Long-Acting Somatostatin Analog Therapy Differentially Alters 68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions
Conclusion: Long-acting octreotide treatment diminished 68Ga-DOTATATE uptake in the liver, spleen, and thyroid but did not compromise tracer uptake in residual primary tumor and metastatic lesions. These findings have a direct impact on the interpretation of 68Ga-DOTATATE PET/CT scans.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Ayati, N., Lee, S. T., Zakavi, R., Pathmaraj, K., Al-Qatawna, L., Poon, A., Scott, A. M. Tags: Clinical Source Type: research
More News: Brain | CT Scan | Liver | Neurology | Nuclear Medicine | PET Scan | Sandostatin | Study | Thyroid | Urology & Nephrology